{"id":"https://openalex.org/W2946835616","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.2515","title":"Distinct immunogenomic properties of melanomas with stable disease as best response to immune checkpoint blockade (ICB).","display_name":"Distinct immunogenomic properties of melanomas with stable disease as best response to immune checkpoint blockade (ICB).","publication_year":2019,"publication_date":"2019-05-20","ids":{"openalex":"https://openalex.org/W2946835616","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.2515","mag":"2946835616"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2019.37.15_suppl.2515","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.2515","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.2515","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089322688","display_name":"Natalie I. Vokes","orcid":"https://orcid.org/0000-0002-3766-5335","observed_orcids":["https://orcid.org/0000-0002-3766-5335"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Natalie Vokes","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056181905","display_name":"Claire A. Margolis","orcid":"https://orcid.org/0000-0002-1019-2419","observed_orcids":["https://orcid.org/0000-0002-1019-2419"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Claire Margolis","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100739514","display_name":"David Liu","orcid":"https://orcid.org/0000-0003-0346-5033","observed_orcids":["https://orcid.org/0000-0003-0346-5033"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Liu","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008750058","display_name":"Bastian Schilling","orcid":"https://orcid.org/0000-0001-8859-4103","observed_orcids":["https://orcid.org/0000-0001-8859-4103"]},"institutions":[{"id":"https://openalex.org/I4210126310","display_name":"Universit\u00e4tsklinikum W\u00fcrzburg","ror":"https://ror.org/03pvr2g57","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210126310"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Bastian Schilling","raw_affiliation_strings":["Department of Dermatology, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany;","institution_ids":["https://openalex.org/I4210126310"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034365278","display_name":"Dirk Schadendorf","orcid":"https://orcid.org/0000-0003-3524-7858","observed_orcids":["https://orcid.org/0000-0003-3524-7858"]},"institutions":[{"id":"https://openalex.org/I4210119759","display_name":"Essen University Hospital","ror":"https://ror.org/02na8dn90","country_code":"DE","type":"funder","lineage":["https://openalex.org/I4210119759"]},{"id":"https://openalex.org/I4391767962","display_name":"Deutsches Konsortium f\u00fcr Translationale Krebsforschung","ror":"https://ror.org/02pqn3g31","country_code":"DE","type":"facility","lineage":["https://openalex.org/I4391767962","https://openalex.org/I4405256427"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Dirk Schadendorf","raw_affiliation_strings":["Universitaetsklinikum Essen & German Cancer Consortium, Essen, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universitaetsklinikum Essen & German Cancer Consortium, Essen, Germany;","institution_ids":["https://openalex.org/I4210119759","https://openalex.org/I4391767962"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039044023","display_name":"Eliezer M. Van Allen","orcid":"https://orcid.org/0000-0002-0201-4444","observed_orcids":["https://orcid.org/0000-0002-0201-4444"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eliezer Mendel Van Allen","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"37","issue":"15_suppl","first_page":"2515","last_page":"2515"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9919999837875366},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.902999997138977},{"id":"https://openalex.org/keywords/stable-disease","display_name":"stable disease","score":0.9900000095367432},{"id":"https://openalex.org/keywords/passenger-mutations","display_name":"passenger mutations","score":0.7730000019073486},{"id":"https://openalex.org/keywords/mhc-class-i-peptides","display_name":"MHC class I peptides","score":0.6809999942779541},{"id":"https://openalex.org/keywords/immune-infiltration","display_name":"immune cell infiltration","score":0.7229999899864197},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.7039999961853027},{"id":"https://openalex.org/keywords/pd-l1","display_name":"PD-L1","score":0.9980000257492065},{"id":"https://openalex.org/keywords/lag-3","display_name":"LAG-3","score":0.9660000205039978},{"id":"https://openalex.org/keywords/interferon-gamma-response","display_name":"interferon-gamma response","score":0.7570000290870667},{"id":"https://openalex.org/keywords/tnf-signaling","display_name":"TNF signaling","score":0.9430000185966492},{"id":"https://openalex.org/keywords/tumor-mutational-burden","display_name":"tumor mutational burden","score":0.5709999799728394},{"id":"https://openalex.org/keywords/anti-ctla-4","display_name":"anti-CTLA-4","score":0.8489999771118164},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.9959999918937683}],"concepts":[{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.7715871334075928},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5402033925056458},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.523499071598053},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5226745009422302},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5187121033668518},{"id":"https://openalex.org/C162317418","wikidata":"https://www.wikidata.org/wiki/Q252857","display_name":"Transcriptome","level":4,"score":0.4731872081756592},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.4687870740890503},{"id":"https://openalex.org/C2781053074","wikidata":"https://www.wikidata.org/wiki/Q21100639","display_name":"PD-L1","level":4,"score":0.4684310853481293},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.40063485503196716},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3531850278377533},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.3072352111339569},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.289051353931427},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.280254989862442},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2794753909111023},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.19972991943359375},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0912180244922638}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2019.37.15_suppl.2515","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.2515","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.2515","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.7400000095367432}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4362525356","https://openalex.org/W4362547186","https://openalex.org/W4283274326","https://openalex.org/W2839753868","https://openalex.org/W2608950674","https://openalex.org/W4384207630","https://openalex.org/W4242864454","https://openalex.org/W2921651111","https://openalex.org/W2187430385","https://openalex.org/W2982130750"],"abstract_inverted_index":{"2515":[0],"Background:":[1],"ICB":[2,42],"has":[3,24],"improved":[4,341],"survival":[5],"in":[6,37,101,117,143,191,211,231,287,309,336],"melanoma.":[7],"Patients":[8],"with":[9,41,103,213,297,319],"stable":[10],"disease":[11,79],"(SD)":[12],"as":[13],"best":[14],"treatment":[15],"response":[16,20,68,151,323],"represent":[17],"an":[18],"intermediate":[19],"phenotype":[21],"whose":[22],"biology":[23],"been":[25],"incompletely":[26],"characterized.":[27],"Methods:":[28],"Whole":[29],"exome":[30],"and":[31,48,149,159,168,173,182,197,204,226,241,304],"transcriptome":[32],"sequencing":[33],"from":[34,295],"pre-treatment":[35],"tumors":[36,164],"melanoma":[38],"patients":[39,102,193,212,245,266,296,318,338],"treated":[40],"(anti-CTLA-4":[43],"and/or":[44],"anti-PD-1)":[45],"were":[46],"assembled":[47],"uniformly":[49],"analyzed":[50],"(WES":[51],"n":[52,56,70,81],"=":[53,57,71,75,82,202,218,256,262,276],"293;":[54],"WES+RNA-seq":[55],"159).":[58],"RECIST":[59],"(v1.1)":[60],"was":[61,89,106,122,228,284],"used":[62,107],"to":[63,96,108,180,195,328],"determine":[64],"complete":[65],"or":[66,77,243],"partial":[67],"(CR/PR;":[69],"94),":[72],"SD":[73,144,156,160,163,192,232,240,265,298],"(n":[74],"42),":[76],"progressive":[78],"(PD;":[80],"157).":[83],"Gene":[84],"set":[85],"enrichment":[86,137],"analysis":[87,185],"(GSEA)":[88],"performed":[90],"on":[91],"50":[92],"\u201challmark\u201d":[93],"gene":[94,141],"sets":[95,142],"identify":[97],"pathways":[98],"differentially":[99],"expressed":[100],"SD.":[104],"CIBERSORT":[105,184],"infer":[109],"relative":[110],"proportions":[111],"of":[112,138,289,317,332],"22":[113],"immune":[114,189,310,322],"cell":[115,177],"types":[116],"each":[118],"sample.":[119],"Mutation":[120,234],"antigenicity":[121,288],"determined":[123],"by":[124],"calculating":[125],"patient-specific":[126],"mutation":[127],"affinity":[128],"for":[129],"MHC":[130],"class":[131],"I":[132],"peptides.":[133],"Results:":[134],"GSEA":[135],"identified":[136,186],"multiple":[139],"immune-related":[140],"tumors,":[145],"including":[146,223],"TNF-\u03b1":[147],"signaling":[148],"interferon-\u0263":[150],"(FDR":[152],"q":[153],"<":[154,206,281],"0.1,":[155],"vs":[157,161,215,249,273,278],"CR/PR":[158,181,196,214,242,250],"PD).":[162],"had":[165,267],"higher":[166,187,230],"HLA":[167],"antigen":[169],"presentation":[170],"pathway":[171],"expression,":[172,222],"increased":[174],"cytolytic":[175],"T":[176],"activity":[178],"compared":[179,194],"PD.":[183],"total":[188],"infiltrate":[190],"PD":[198,216,244,258],"(Mann-Whitney":[199],"U":[200,254],"p":[201,205,255,261,275,280],"0.03":[203],"0.001,":[207],"respectively)":[208],"but":[209],"not":[210,237],"(p":[217],"0.124).":[219],"However,":[220,264],"checkpoint":[221],"PD-1,":[224],"PD-L1,":[225],"LAG3,":[227],"also":[229],"patients.":[233],"load":[235],"did":[236],"differ":[238],"between":[239],"(SD":[246,272],"median":[247,251,259],"2.87":[248],"7.98,":[252],"Mann-Whitney":[253],"0.104;":[257],"3.42,":[260],"0.210).":[263],"more":[268,300],"antigenic":[269,301],"passenger":[270,302],"mutations":[271,303],"CR/PR,":[274],"0.001;":[277],"PD,":[279],"0.001);":[282],"there":[283],"no":[285],"difference":[286],"driver":[290],"mutations.":[291],"Conclusions:":[292],"Pre-treatment":[293],"melanomas":[294],"contain":[299],"demonstrate":[305],"a":[306,315],"global":[307],"increase":[308],"signaling.":[311],"This":[312],"may":[313,339],"describe":[314],"subset":[316],"pre-existing":[320],"dysfunctional":[321],"that":[324],"is":[325],"minimally":[326],"responsive":[327],"ICB.":[329],"Further":[330],"characterization":[331],"the":[333],"tumor-immune":[334],"interaction":[335],"these":[337],"inform":[340],"interventions.":[342]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1}],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2025-10-10T00:00:00"}